All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
The 60th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from 1–4 December 2018. The content of two oral presentations regarding clinical trials for high-risk smoldering MM (SMM) is outlined below. Both studies were from Irene M. Ghobrial’s group from the Dana-Farber Cancer Institute, Boston, US.
On Saturday 1 December 2018, during an oral abstract session entitled: Myeloma: Therapy, excluding Transplantation: Novel Targeted Combinations in Myeloma, Irene M. Ghobrial presented data from a phase II clinical trial for SMM.1
Recent studies have shown that early treatment of SMM may delay or prevent the progression to MM. This phase II trial uses a triplet regimen of elotuzumab, lenalidomide, and dexamethasone to treat high-risk SMM patients and examines the progression-free survival (PFS) of patients after two years from the time of treatment initiation.
Secondary outcome measures include the response rate, time to disease progression, duration of response, overall survival (OS), and safety of the combination treatment.
The elotuzumab, lenalidomide, dexamethasone triplet is well-tolerated in patients with high-risk MM and results in 95% PFS, 36 months after initiation of treatment. Ongoing studies will determine how the immune profile correlates with the response or resistance to treatment.
On Monday 3 December 2018, during an oral abstract session entitled: Myeloma: Therapy, excluding Transplantation: Novel Proteasome Inhibitors, Mark Bustoros presented data from another phase II clinical trial for SMM.3
This phase II trial examined the triplet combination of ixazomib, lenalidomide, and dexamethasone (IRd) for patients with high-risk SMM. The primary outcome of the trial was progression-free survival (PFS) two years after initiation of treatment.
Secondary objectives included assessment of response rate and duration, the safety of the triplet combination, depth of response and minimal residual disease (MRD).
The all-oral triplet combination of ixazomib, lenalidomide, and dexamethasone shows minimal toxicity and high response rates for patients with high-risk SMM, opening an avenue for future studies and longer follow-ups to monitor disease progression.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox